Get the Daily Brief
Latest Biotech News
Fecal exfoliome (Foli‑seq) validated — new noninvasive window into gut immune state
Columbia University researchers introduced exfoliome sequencing (Foli‑seq), a targeted amplicon approach that profiles host RNAs from exfoliated gut cells in feces to monitor intestinal and immune...
Solid licenses AAV‑SLB101 to Andelyn — next‑gen capsid expands CDMO offerings
Solid Biosciences granted Andelyn Biosciences a non‑exclusive worldwide license to use AAV‑SLB101, Solid’s next‑generation capsid engineered for enhanced skeletal muscle and cardiac tropism with...
FDA tightens Elevidys label: myocarditis warnings and use limits
The FDA updated the prescribing information for Sarepta Therapeutics’ gene therapy Elevidys (for Duchenne muscular dystrophy), adding stronger myocarditis language and troponin‑I monitoring...
J&J pays $3.05B for Halda: buys RIPTAC 'hold-and-kill' platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, securing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD‑0915 for...
Merck snaps up Cidara for $9.2B: targets long‑acting influenza prevention
Merck agreed to acquire Cidara Therapeutics for $9.2 billion to add CD388, a long‑acting, strain‑agnostic antiviral currently in Phase III (ANCHOR) for influenza prevention in high‑risk...
Zanidatamab beats trastuzumab: Phase III HERIZON‑GEA‑01 posts positive topline data
Partners Zymeworks, Jazz Pharmaceuticals and BeOne Medicines announced positive topline results from the Phase III HERIZON‑GEA‑01 trial: zanidatamab (Ziihera) plus chemotherapy improved...
Roche's oral SERD clears planned interim: adjuvant breast cancer hit
Roche reported a planned interim success in a Phase III adjuvant trial of its oral selective estrogen receptor degrader, giredestrant, showing the agent reduced early recurrence when given after...
NIH grant cuts halt 383 trials — 74,311 participants left in limbo
A Harvard‑led analysis published in JAMA Internal Medicine found NIH funding cuts from late February to mid‑August led to termination of 383 trials, affecting more than 74,000 enrolled...
Iambic raises $100M to move AI‑discovered oncology candidates toward clinic
Iambic secured $100 million to advance AI‑discovered oncology drugs into clinical testing, following presentation of data for a breast cancer candidate at a recent oncology conference. The...
Solve Therapeutics pulls in $120M: targets best‑in‑class ADCs
Solve Therapeutics closed a $120 million financing round to develop next‑generation antibody‑drug conjugates, including novel linker technologies the company says can improve therapeutic index and...
Rapid sepsis test matches blood culture: Ocean Dx hits 100% sensitivity & specificity
Ocean Dx reported a clinical evaluation in which its rapid sepsis assay matched the gold‑standard reference, returning 100% sensitivity and 100% specificity against blood cultures while...
Foli‑seq captures the 'exfoliome': noninvasive fecal RNA tool maps gut immune states
Researchers introduced exfoliome sequencing (Foli‑seq) — a targeted, multiplexed amplicon approach that profiles host mRNA from exfoliated gut cells in feces — and demonstrated the method can...
Neural stem cell transplant restores primate forelimb function — major translational step
A Nature Biotechnology study reported that transplanting human embryonic stem cell‑derived spinal cord neural stem cells (H9‑scNSCs) into injured rhesus monkeys restored forelimb and hand function...
J&J buys Halda for $3.05B: acquires RIPTAC platform and lead prostate drug
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, securing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD-0915....
Ziihera Phase 3: zanidatamab shows PFS and OS gains in first-line GEA
Zymeworks and partners Jazz Pharmaceuticals and BeOne announced positive topline results from the Phase 3 HERIZON‑GEA‑01 trial testing zanidatamab (Ziihera) with chemotherapy, with and without...
Stem cell transplant restores primate hand function: path to clinical translation
Two Nature Biotechnology reports revealed that transplanting human embryonic stem cell‑derived spinal cord neural stem cells restored forelimb/hand function in nonhuman primates with cervical...
Foli‑seq: fecal exfoliome sequencing maps gut immune and epithelial states
Researchers at Columbia University unveiled exfoliome sequencing (Foli‑seq), a targeted amplicon approach that profiles host mRNA from exfoliated gut cells in feces to monitor intestinal and...
Roche previews Axelios 1: fast SBX sequencing shows cancer‑genomics promise
Roche and early users presented early data for the Axelios 1 sequencing‑by‑expansion (SBX) nanopore platform at AMP, positioning the instrument for rapid cancer genomics and ctDNA analysis....
Thermo Fisher pushes next‑day comprehensive genomic profiling on Genexus
Thermo Fisher presented multicenter data showing its Oncomine Comprehensive Assay Plus running on the automated Ion Torrent Genexus platform can deliver comprehensive genomic profiling (CGP) with...
Ocean Dx sepsis test matches gold standard: 5‑hour, direct whole‑blood assay
A clinical evaluation showed Ocean Dx’s rapid sepsis assay detected more than 1,000 bacterial species directly from whole blood with 100% sensitivity and 100% specificity versus reference blood...